Posts Tagged ‘nursing homes’

All Classes of Psychiatric Drugs Found Equally Dangerous for Nursing Home Residents

Monday, March 28th, 2011

MedicalNews Today March 28, 2011

Conventional antipsychotics, antidepressants and benzodiazepines often administered to nursing home residents are no safer than atypical antipsychotics and may carry increased risks, according to an article in CMAJ (Canadian Medical Association Journal).

Psychotropic medications are often used to manage behavioral symptoms in seniors, particularly people with dementing illnesses, with up to two-thirds of dementia patients in nursing homes prescribed these medications. However, the effectiveness of these drugs in this indication is unclear and important safety concerns exist, especially related to antipsychotics.

Psychotropic or psychoactive medications act upon the central nervous system and are prescribed for the management of mental and emotional disorders. They include, amongst others, first and second generation antipsychotics (also known as conventional and atypical antipsychotics), antidepressants, benzodiazepines and other sedatives. Despite their widespread use, none of these treatments has been approved by the FDA or Health Canada for the management of behavioral symptoms associated with dementia.

A team of researchers from Brigham and Women’s Hospital in Boston, Massachusetts, undertook the study to evaluate the comparative safety of various psychotropic medication classes, focusing on patients in nursing homes because of the extensive use of these drugs in this setting and the complexity of these patients’ illnesses. The study cohort included all BC residents admitted to a nursing home between Jan. 1, 1996 and March 31, 2006 and who received a psychotropic drug within 90 days of admission.

Of the 10 900 patients in the study, 1942 received an atypical antipsychotic, 1902 a conventional antipsychotic, 2169 an antidepressant and 4887 a benzodiazepine. Rigorous methodological approaches were applied to ensure this non-randomized study was not affected by the selective prescribing that tends to occur in routine care.

“In 10 900 older adults newly admitted to nursing homes in BC who began taking psychotropic medications, we observed risks of death that were higher among those who initiated conventional antipsychotics, antidepressants and benzodiazepines. We also observed risks of femur fracture that were higher with conventional antipsychotics, antidepressants and benzodiazepines used for anxiety, all compared with atypical antipsychotics. No clinically meaningful differences were observed for risk of pneumonia or heart failure, except possibly a lower risk of pneumonia and a higher risk of heart failure with benzodiazepines,” state the authors.

They conclude that a large randomized trial is required to confirm their findings but that clinicians should weigh the increased risks against potential benefits when considering prescribing these medications for their patients in nursing homes.

http://www.medicalnewstoday.com/articles/220129.php

« Return to news items


Share

The verdict is in: Johnson & Johnson misled physicians in Risperdal marketing campaign

Friday, March 25th, 2011

McKnights – March 25, 2011

A jury in South Carolina on Tuesday found Johnson & Johnson’s pharmaceutical unit, Ortho-McNeil-Janssen, guilty of misleading doctors about the safety and effectiveness of the anti-psychotic drug Risperdal.

Janssen violated South Carolina’s consumer protection laws in 2003 when it sent a letter to roughly 7,200 doctors in the state touting the safety and effectiveness of Risperdal, the jury decided. Civil penalties could total more than $35 million, or $5,000 for each letter Janssen sent, according to a Bureau of National Affairs report. That hearing will take place April 18-19.

Johnson & Johnson has been embroiled in numerous legal battles surrounding its marketing of Risperdal. The company is alleged to have paid millions of dollars in kickbacks to pharmaceutical giant Omnicare to influence Risperdal sales to nursing home residents. The South Carolina case is one of 12 state-led cases against the company, according to BNA.

http://www.mcknights.com/the-verdict-is-in-johnson-johnson-misled-physicians-in-risperdal-marketing-campaign/article/199127/

« Return to news items


Share

Questions Raised Over Antipsychotic Usage On Elderly

Thursday, March 3rd, 2011

Groups Trying To Prevent Misuse Of Psychoactive Drugs On Elderly Patients

10News.com- San Diego

March, 2, 2011

The 10News I-Team has learned many local skilled nursing facilities are using powerful drugs to control elderly patients’ behavior.Keith Blair suffered from mild dementia, and it wasn’t until after his death that his daughter, Marian Hollingsworth, realized he’d been given antipsychotic drugs.

“It’s a way of controlling them. It keeps him in bed,” said Hollingsworth.Until that realization, Hollingsworth was puzzled by her father’s rapid deterioration. He had been given the powerful antispychotics Risperdal and Haldol without her permission.”Antipsychotic drugs are for the treatment of mental illness, not dementia,” said Tony Chicotel of California Advocates for Nursing Home Reform (CANHR). “And now we’ve got studies that show just horrific outcomes for people with dementia who take these drugs and that they’re prescribed just as much as they ever were, if not more.

CANHR is trying to end the misuse of psychoactive drugs to control seniors. The group created a website which allows anyone to see how many patients are receiving psychoactive drugs at any skilled nursing facility in California. Experts say while using these drugs is sometimes justified, there are dangers in their misuse.”When you see nursing homes that are above 90 percent of their residents are receiving a psychotropic drug, you’re wondering what the hell is going on there,” said Chicotel.
read the rest of the story here: http://www.10news.com/news/27059153/detail.html

Visit the California Association for Nursing Home Reform website for their Campaign to Stop Chemical Restraints in Nursing Homes

http://www.canhr.org/stop-drugging/

« Return to news items


Share

Is J&J Cooking Its Books? Suit Alleges Double-Counting at the Pharma Giant

Wednesday, March 2nd, 2011

BNET – March 1, 2011

by Jim Edwards

A whistleblower lawsuit filed against Johnson & Johnson (JNJ) didn’t get much attention in the media because the unproven accusations within it — paying kickbacks to nursing home pharmacy Omnicare (OCR) — sounded familiar. But the details in the complaint are worth exploring because they go further than the usual allegations of paying for no-work contracts to boost pharmacy distribution of their drugs.

Plaintiff Scott Bartz, a former sales compensation manager at J&J, alleges that the company is cooking its books in two ways, both of which could lead to prison time for senior managers if his allegations are true:

  • The company is overstating its revenues by counting the discounts it pays to drug repackagers under the “cost of goods sold” line on its income statement. COGS are supposed to reflect manufacturing and shipping costs, not price discounts and rebates.
  • The company is double-counting sales of the injectable antipsychotic Risperdal Consta as the drug passes through wholesalers and retailers. The double-counting is part of a “channel-stuffing” scheme in which the company falsely inflates its sales by counting shipments to wholesalers as if they were actual sales at the retail level.

J&J has yet to respond to the suit, which was unsealed in December and didn’t surface in regulatory filings until last week. The company will be comforted by the fact that the Department of Justice has so far declined to intervene. That doesn’t necessarily mean the DOJ believes the case is without merit; the DOJ chooses its cases based on a range of criteria, including policy priorities and available resources. Nonetheless, the accusations should be taken with a pinch of salt until J&J responds.

The last time channel stuffing reared its ugly head in the drug industry was when Bristol-Myers Squibb (BMS) settled fraudulent accounting charges with the SEC for $150 million. In that case, BMS’ former president and CFO were indicted for fraud and conspiracy, but the charges were dropped last year in favor of a pair of deferred-prosecution agreements and $400,000 in fines.

Bartz worked for J&J from 1999 to 2007 and had responsibility for analyzing J&J’s financial and sales data from companies such as IMS Health, a market research company whose information is used as an industry benchmark. In 2004 and 2005, Bartz noted an alleged discrepancy between the amount of Risperdal Consta J&J sold to three wholesalers and the amount that pharmacies actually sold to patients:

  • J&J’s Risperdal Consta sales to wholesalers McKesson, Cardinal and AmeriSource Bergen
  • 2004: $130 million reported; $75 million actually sold
  • 2005: $285 million reported; $145 million actually sold

Bartz investigated, and found further alleged discrepancies. Alkermes, the company that makes Risperdal for J&J, reported worldwide sales to J&J’s Janssen unit worth $1 billion in 2005, Bartz alleges. But Janssen’s net sales of that drug in the same year were only recorded as $664 million; and sales from outlets and other distributors were $390 million, Bartz claims. J&J concealed its channel-stuffing scheme by counting the same sales twice, Bartz claims (click to enlarge):

The discrepancy between the sales J&J racked up with its wholesalers and actual sales at retail and pharmacy level did not go unnoticed, Bartz claims. An IMS Health executive said that there seemed to be “very little sellout” of some Risperdal Consta shipments that J&J had sent to McKesson:

Bartz alleges channel stuffing was widespread at J&J:

Plaintiff has also discovered that the practice of channel stuffing was used in all or most of the J&J products as a means to increase profit margins of distributors such as McKesson, Cardinal and AmeriSource Bergen.

For investors, the most serious allegation Bartz has to make is furnished with the least detail. He claims that J&J inflated sales of the Alzheimer’s drug Razadyne through a number of different schemes, including removing sales from the company’s books only to reinsert them once the books were closed at year’s end, and pretending that discounts J&J offers to repackagers on the drug are manufacturing costs:

That scheme would allow J&J to pretend it is making more money on the drug than it actually is, albeit at smaller margins. Oddly, the net effect of such a scheme on J&J’s bottom line would be a wash, but it would give outside observers the impression that the market for Razadyne is bigger than it actually is.

Bartz claims he was harassed and demoted after he complained to management that he believed the company’s accounting was false. He claims he had a stress-induced heart attack before he was finally terminated in 2007.

http://www.bnet.com/blog/drug-business/is-j-j-cooking-its-books-suit-alleges-double-counting-at-the-pharma-giant/7552

« Return to news items


Share

Senate Aging Panel Blows Whistle on Over Drugging Dementia Patients

Tuesday, March 1st, 2011

“Beautiful young people are accidents of nature, but beautiful old people are works of art.” — Eleanor Roosevelt

Natural News,  March 1, 2011

by Monica G. Young

Pharmaceutical companies view the elderly as a lucrative market. However a panel of experts at the recent Senate Aging Committee forum decided to speak up. Over-medication occurs far too often in those diagnosed with dementia, the panel warned, and as baby boomers age the problem will only worsen.

One reason overmedication occurs, per this panel, is family members, caregivers, and nursing home workers often misinterpret patients’ complaints about physical ailments as unruly or aggressive conduct. To manage their behavior, such patients are administered antipsychotics they don’t need.

About five million patients are currently diagnosed with Alzheimer’s and other forms of dementia. “Those in this field have a feeling we’re headed in a very fast train toward the end of a cliff,” stated Patricia Grady, PhD, director of the National Institute of Nursing Research.

Director of California Advocates for Nursing Home Reform, Patricia McGinnis, demanded nursing homes be held “accountable” for the drugs they administer. “The way anti-psychotic drugs are used in nursing homes is a form of elder abuse,” she told the forum. “Instead of providing individualized care, many homes indiscriminately use these drugs to sedate and subdue residents.”

McGinnis urged for more informed consent before antipsychotics are given. She cited her own 89-year-old mother who was hospitalized for a broken hip, discharged to a nursing home and given an antipsychotic. McGinnis said her mother did not have dementia and didn’t need the drug, and family members were never consulted.

Professor of Nursing at the University of Wisconsin, Christine Kovach, spoke of an elderly patient who kept saying “No, no, no” and protesting whenever someone tried to move her. She was put on an anti-psychotic. X-rays later disclosed an untreated broken hip.

Nonpharmacological approaches can help, said Laura Gitlin, PhD, Director of the Jefferson Center for Applied Research on Aging and Health in Philadelphia. She listed alternatives like personal counseling, education, skill training of family members, and simple and engaging activities.

Antipsychotics have been widely used to squelch disruptive behavior among people with dementia. However these drugs are especially life-threatening to older people, raising the risk of strokes, diabetes and falls.

“There’s a bunch of problems, not least of which is those drugs can kill you,” reported Dr. Mark Kunik at Baylor College of Medicine in Houston at the annual Gerontological Society of America’s meeting. Instead of looking for physical causes of disruptive behavior, doctors typically prescribe drugs for dementia patients, he said, because “It’s the easy thing to do. … That’s true in hospitals, in clinics and in nursing homes.”

“Whether you have Alzheimer’s or not, there’s a reason people get frustrated or upset — pain, urinary tract infections, hunger, fear of strangers or loud noises or strange settings, maybe drug interactions,” Kunik stated. “If you figure that out, you likely can find a safer, nonpharmacologic treatment.”

There are alternatives that work. Eva Lanigant, a resident care coordinator for a facility in Minnesota, was tired of seeing elderly patients drugged into a stupor. Working with a psychiatrist and a pharmacist, she started a project to replace drugs with massage, games, exercise, personal attention, better pain control and other techniques. They trained the entire staff to interact with dementia residents.

Within six months they eliminated antipsychotic drugs and cut antidepressant use by half. Lanigan reported, “The chaos level is down, but the noise is up: the noise of people laughing, talking, much more engaged with life.  It’s amazing.”

« Return to news items


Share

Federal Judge & DOJ back lawsuit accusing Johnson & Johnson of illegal kickback scheme to push antipsychotic drugs on elderly

Tuesday, March 1st, 2011

AboutLawsuits.com

March 1, 2011

A federal judge has refused to toss out a whistleblower lawsuit backed by the Department of Justice (DOJ), which accuses Johnson & Johnson of involvement in an illegal kickback scheme to push their antipsychotic drugs on elderly nursing home residents that did not need them.

Johnson & Johnson sought to have claims brought by the DOJ, a number of whistleblowers and states dismissed, saying that what the plaintiffs are calling illegal kickbacks were completely legal rebates. However, U.S. District Judge Richard Stearns found that plaintiffs had sufficient evidence to go forward with the complaint.

Judge Stearns did remove several plaintiffs from the case, including the states of Nevada, Texas and Illinois, but allowed Kentucky, Indiana and Virginia to stay part of the lawsuit. Whistleblower David Kammerer was also removed from the lawsuit.

The DOJ filed a civil False Claims Act compliant against J&J on January 15, 2010, saying that the company paid millions to Omnicare, Inc. as kickbacks for selling Risperdal to nursing home patients.

In 2009, Omnicare settled charges brought against it by the government for allegedly paying kickbacks to nursing homes to prescribe the drug. At that time, the Justice department investigators indicated that the illegal nursing home drug kickbacks were hidden as data fees, education fees and as payments to attend Omnicare meetings.

According to the DOJ complaint against Johnson & Johnson, the drug maker paid $50 million to Omnicare between 1999 and 2004 to get it to prescribe Risperdal to elderly patients with dementia, and then hid those kickbacks as payments for services that Omnicare never actually provided. Omnicare then enacted intervention programs such as the “Risperdal Initiative” to persuade physicians to prescribe the drug to elderly dementia patients.

Omnicare, the largest pharmaceutical supplier for nursing homes in the U.S., has pharmacists on staff who review patients’ records and then makes recommendations to the patients’ physicians. Those recommendations are followed about 80% of the time, the DOJ said.

The claims were originally made by Omnicare pharmacist Bernard Lisitza in 2003, and the DOJ chose to intervene on Lisitza’s behalf.

Whistleblowers who report a false claim against the government may be entitled to receive a portion of any money that the government recovers from the offenders under the qui tam provision of the False Claims Act. In return, the whistleblower must be the first to bring the case to the government’s attention, and must not publicize the claim until the DOJ decides to prosecute the claim.

Risperdal (risperidone) is manufactured by Janssen, a division of Ortho-McNeil-Janssen, which is a subsidiary of Johnson & Johnson. Risperdal is approved by FDA for the treatment of schizophrenia, bipolar disorder and autism, but it is commonly used among elderly with dementia and sometimes as a form of chemical restraint in nursing homes.

Risperdal is not approved for treatment of dementia, and patient advocates have been pushing nursing homes to reduce the use of the drug among elderly due to the health risk and a lack of actual health benefits. According to a recent report from the United Kingdom, side effects of Risperdal and other similar antipsychotics, like Seroquel, Zyprexa and Abilify, could be linked to as many as 1,800 deaths and 1,620 strokes per year in elderly patients with dementia.

http://www.aboutlawsuits.com/risperdal-omnicare-lawsuit-proceeds-16571/

To see more international drug regulatory warnings and studies on Risperdal and other antipsychotic drugs, visit CCHR’s Psychiatric Drug Side Effects Database here: http://www.cchrint.org/psychdrugdangers/drug_warnings.php

« Return to news items


Share

Now this, is the kind of mental therapy we can get behind—”Psychiatrist tries a different approach with dementia patients”

Tuesday, January 4th, 2011

STAFF PHOTO / CRAIG LITTEN - Dr. Miguel Rivera visits with patient Helen Kidd last month at the Pines of Sarasota. Under Rivera's direction, Pines caregivers have deployed some simple spa comforts to reduce agitation. As a result, dosages of antipsychotic drugs have dropped.

Herald Tribune
By Barbara Peters Smith
January 2, 2011

The pixie-like patient in a pink dress and a long, flirty strand of pearls lights up as visitors approach, and scoots her wheelchair along the corridor to give them her standard greeting.

“Okinawa! Saipan! Iwo Jima! Rome!” she chirps, alluding to the military career that took her around the world — long before dementia brought her here, to the Garden Memory Unit at Pines of Sarasota.

She tags along as the visitors inspect a shower room that has been freshly painted with an expansive scene of Gulf-front sand and sky. Isn’t that the most beautiful thing you’ve ever seen?” she asks them. “I love it in there!”

One of the Pines’ calming shower rooms.

Dementia patients can get anxious to the point of violence while bathing, and this cheery beach mural is one of many small innovations that have lifted moods here in recent months. Under the direction of psychiatrist Dr. Miguel Rivera, caregivers at the Pines have deployed such simple spa comforts as music, massage and calming colors to help reduce agitation. As a result, dosages of antipsychotic medications have dropped to less than half the state average for this most challenging patient population.

Rivera, a gentle, sweet-spoken native of Puerto Rico who completed his psychiatric residency at the University of South Florida in 2001, stresses that none of these therapeutic tactics are his own invention.

“These were not things they taught us in our residency program, but I didn’t create them, either,” he says. “I’m more the person that maybe has the credentials to bring this to people, and people will tend to believe me because I have this M.D. behind my name.”

But Pam Polowski, the Alzheimer’s Association program specialist for Sarasota County, says Rivera works a kind of magic that is rare in this field.

“One of the things that is really important to know is that we can’t drag our dementia patients into our world,” Polowski says. “We have to go to their world and join them on that journey. And he gets that.”

Dementia is a loss of brain function that cripples memory, emotions and behavior. Medicare payments for services to dementia patients are expected to total $172 billion in 2010. So low-cost interventions such as Rivera’s could save tax dollars.

In a light-filled common room at the Pines, activities director Shirley Riesz is using karaoke to help 20 or so residents power through the normally trying hours before suppertime. Dementia patients’ circadian rhythms can make them prone to “sundowning,” Rivera explains, when they “begin to pace, get aggressive, want to go home and set off alarms” on the unit’s doors to the outside world.

A music therapy session at any long-term care facility can be a dreary, halfhearted ritual. But here, the atmosphere is alive. As “High Hopes” plays, Riesz holds the microphone for a man who sings out strongly, “Whoops, there goes another rubber tree plant!”

Even those not joining in are attentive and mostly smiling. Several wave at Rivera, and he waves delightedly back.

“They don’t know I’m a doctor,” he said, indicating his casual, golf-style shirt. “They just think I’m this friendly guy who comes around a lot.”

Through research and trial and error, Rivera has discovered that what he calls “courting music” — from the days when his patients were young and in love — evokes the most dramatic responses. He explains that the vivid connection between a particular song and a potent emotion reflects “things that the mind doesn’t really know. If you are really able to concentrate and visualize through music, you get transported and the body responds.”

Rivera tells the story of Ann, who moved to the memory unit from the assisted-living section of the Pines after a stroke. Unable to speak, she was despondent and withdrawn.

“I had the intuition that what we really needed to do was to start her on a singing program,” he recalls. “We started to notice early on that she was able to sing words and phrases that she was not able to speak. Little by little, it started to spill into her day. She started saying ‘OK’ or ‘yes’ or ‘no.’ We never knew that she liked coffee until the other day, when she told Shirley, ‘I love coffee.’ So now she gets to enjoy her coffee.”

And there is Grace, the patient so upset by the bathing process that she was giving her attendant bruises.

“This is a Monday ritual without fail,” Riesz wrote in a recent e-mail message to Pines education director Joann Westbrook. “But today there was NO screaming, just laughing, dancing and singing.”

The song that did the trick, according to certified nurse assistant Valrie Miller, was “Will You Love Me Tomorrow?” After the first nonviolent bath time, Miller says, Grace asked her, “Will you love me today?”

Thanks to a small grant that paid for iPods and “courting music”; waterproof plastic iPod holders made by Rivera’s neighbor, a retired engineer; and those calming beach scenes painted by Westbrook’s husband, K.C. Higgins, the Pines found a way to do for Grace what the strongest pharmaceuticals could not.

“What is ironic,” Riesz added, was that “her daughter gave me a preferred music CD and it has no connection or relation to the genre she was enjoying. Let that be a lesson to us: Make up your preferred playlist of music now, because someday your children may do it for you.”

Rivera, who works as a mental health medical director for seven long-term care facilities in Sarasota, did not plan any of this.

He came to Sarasota in 2001 with what he now calls the “grandiose” idea of running an alternative, yoga-based medical practice that would “teach people how to change their lives.” The business failed.

“Right around the same time that this is disappearing,” he says, “I get a call from Bruce Robinson, the chief of geriatrics at Sarasota Memorial. And he said, ‘Hey, I heard you were in Sarasota; would you mind doing some nursing home consultations for me?’ They say in Spanish, when you’re born to be a hammer, it rains nails from the skies.”

Robinson says finding trained psychiatrists to take on this work is a struggle.

“There’s a desperate need for more mental health care in long-term facilities,” he says. “It’s a shame there aren’t more doctors like Miguel. He’s there. He answers his phone.”

Rivera took to his mission right away. But he was frustrated that his only option for helping distraught patients was to increase their medications.

“I remember so many times walking through that old west hallway at the Pines” before the building was remodeled, he says. “After the first few years of me working there and seeing how people were overmedicated, and boredom was so prevailing, I remember — and I feel it right now — just walking down that hall, and praying, saying, ‘Please, God, show me a way.’ ”

It was Rivera’s wife, Natasha, he says, who put him on a path to exploring alternatives to drugs. Both practitioners of TriYoga, they met in 2007 on a spiritual trip to India. By the end of the three-week stay, they were married. A year later, she joined him in Sarasota from her native Russia. And almost immediately, Rivera says, she changed the way he was doing his job.

“All of a sudden there is this fresh pair of eyes that is asking all these questions,” he says. “‘What is Alzheimer’s disease? Why do people get it?’ It made me look at things; it took me out of that automatic mode.”

Rivera soon found research on the use of music, massage and other therapies on dementia patients. His reading also led to the use of daily affirmations by Pines staffers, who tell the patients, “You are safe; you are loved; you are happy.” The result, says Westbrook of the Pines, was “this whole beautiful circle he has created here that has changed that unit.”

Robinson views Rivera’s work from a more scientific standpoint, and applauds the fact that out of some 40 patients in the Pines memory unit, only eight are taking antipsychotic drugs.

“I am happy to have them report that,” he says. “Since the only evidence we have for the effects of antipsychotics is that they kill people, anything that can reduce that is a good thing.

“The life of an old person with dementia can be very meager: Where’s the fun?” Robinson adds. “The idea of having something positive in your life, like massage — all those things have an evident face validity.”

Read the rest of the article here:  http://www.heraldtribune.com/article/20110102/ARTICLE/101021037/2055/NEWS?p=1&tc=pg

« Return to news items


Share

The Way Antipsychotics Are Used in Nursing Homes Called “A form of elder abuse” by Patient Advocates

Monday, December 13th, 2010

NurseWeek—Dec 13, 2010

Over-medication of dementia patients is a looming problem as the number of such patients in the U.S. continues to grow, a panel of experts told a Senate Aging Committee forum on Dec. 8.

Panelists said over-medication, sometimes with anti-psychotic drugs, frequently occurs with dementia patients because caregivers or family members may mistake complaints of physical illness for unruly behavior.

Patricia McGinnis, executive director of the California Advocates for Nursing Home Reform, said nursing homes must be “accountable” for the drugs they administer.

“The way anti-psychotic drugs are used in nursing homes is a form of elder abuse,” McGinnis told the forum. “Instead of providing individualized care, many homes indiscriminately use these drugs to sedate and subdue residents.”

By learning more about residents to understand their needs and personalities, and establishing work schedules that allow staff to consistently work with the same residents, according to panelists, nursing homes can reduce the use of drugs as a solution to unruly behavior by dementia patients.

Non-drug approaches also can be helpful for caregivers, according to panelist Laura Gitlin, PhD, director of the Jefferson Center for Applied Research on Aging and Health at Thomas Jefferson University in Philadelphia.

She said that providing at-home caregivers with specific skills training in stress reduction, communication and problem-solving techniques can reduce depression and improve self-rated health, sleep quality and overall well-being.

Gitlin described an occupational program at her university that developed meaningful activities for dementia patients based on their capabilities. The program cost $941.63 per family per year, compared with $1,825 for drug treatment programs. The program also saved caregivers about five hours a day in time they would have otherwise spent in hands-on care.

http://news.nurse.com/article/20101213/NATIONAL02/112130006/-1/frontpage

« Return to news items


Share

Nation of Pill Poppers: 19 Potentially Dangerous Drugs Pushed By Big Pharma

Tuesday, December 7th, 2010
AlterNet — December 6, 2010
by Martha Rosenberg
Here are some of the dicey drugs many Americans are hooked on,
thanks to greedy pharmaceutical companies.

Since direct-to-consumer drug advertising was legalized 13 years ago, Americans have become a nation of pill poppers — choosing the type of drug they desire like a new toothpaste, sometimes whether or not they need it.

But if patients want the drugs, doctors and pharma executives want them to have the drugs and media gets full page ads and huge TV flights (when many advertisers have dried up), is the national pillathon really a problem?

Yes, when you consider the cost of private and government insurance and the health of patients who take potentially dangerous drugs like these.

Seroquel, Zyprexa, Geodon, atypical antipsychotics

Even though the antipsychotic Seroquel surpasses 71 drugs on the FDA’s January quarterly report with 1766 adverse events, even though it’s linked to eight corruption scandals, even though military parents blame Seroquel for unexplained troop deaths, it is the fifth biggest-selling drug in the world and netted AstraZeneca almost $5 billion last year.

Atypicals were originally promoted to replace side-effect prone drugs like Thorazine but soon became pharmaceutical Swiss Army Knives for depression, anxiety, insomnia, bipolar and conduct disorders and other off label uses — and betrayed the same side effects as older antipsychotics. (Especially tardive dyskinesia-linked Abilify.)

Foisted disproportionately on the young, poor and disadvantaged, atypicals cause such weight gain and metabolic derangement — 16 percent of Zyprexa patients gain 66 pounds and some gain over 100 — manufacturer Lilly Eli Lilly agreed to pay the state of Alaska $15 million in 2008 for the Medicaid costs of Zyprexa patients who developed diabetes.

Atypicals carry warnings of death in demented patients but are widely used in nursing homes. And even though Risperdal maker Johnson & Johnson, Geodon maker Pfizer, Abilify maker Bristol-Myers Squibb, Lilly and AstraZeneca have all entered into government settlements that acknowledge fraudulent or wrongful atypical marketing, FDA rewarded atypical makers by approving Zyprexa and Seroquel for children last year. And approved a new atypical antipsychotic, Latuda, in October. Maybe the FDA is bipolar.

Ritalin, Concerta, Strattera, Adderall and ADHD drugs

When it comes to the epidemic of 5.3 million US children between 3 and 17 diagnosed with ADHD, suspicions of pharma pushing the disorder are exceeded only by pharma’s admissions thereof.

During an August conference call with financial analysts, Shire specialty pharmaceuticals president Mike Cola credited the “very dynamic ADHD market” to Shire’s globalization efforts and “investments we have made in new uses for our existing products.”

Those uses, a.k.a. diagnoses, for Shire products like stimulants Adderall, Vyvanse and Intuniv include adult ADHD, cognitive impairment, depression and excessive daytime sleepiness.

Still, Cola says despite the 10 percent ADHD “new starts” that are helping Shire “grow the market,” and the “co-administration market” of add-on prescription drug$, the ADHD franchise suffers from patients who drop out when they quit seeing their pediatrician. “We don’t see those patients show up again until their mid-to-late 20s,” laments Cola.

ADHD drugs, in addition to “robbing kids of their right to be kids, their right to grow, their right to experience their full range of emotions, and their right to experience the world in its full hue of colors,” as Anatomy of an Epidemic author Robert Whitaker puts it, can also be deadly.

A 2009 article in the American Journal of Psychiatry called Sudden Death and Use of Stimulant Medications in Youths found 1.8 percent of youthful stimulant users died sudden deaths from cardiac dysrhythmia or unexplained causes versus 0.4 percent who were not on stimulants. Though it helped fund the study, the FDA said the results proved no “real risk” and kids should keep taking their meds.

Meanwhile, says Robert Whitaker, kids on ADHD meds “are told they are going to be on these drugs for life. And next thing they know, they’re on two or three or four drugs,” a phenomenon also known as the co-administration market.

Prozac, Paxil, Zoloft, SSRIs

Selective serotonin reuptake inhibitor (SSRIs) antidepressants like Prozac, Paxil, Zoloft and Lexapro probably did more to inflate pharma profits in the last decade than direct-to-consumer advertising and Viagra put together, no pun intended: over 60 million prescriptions were filled in the US in 2007 with many patients reporting their depression lifted.

But some critics say for mild depression, SSRIs don’t work at all and are no better than placebo.

And others say they can add aggression, bizarre behavior, self-harm and suicidal thoughts to depression. In fact, there are 4,200 published reports of SSRI-related violence, aggression, bizarre behavior, self-harm and suicide since the drugs were introduced in 1988 including the well known gun massacres at Columbine (1999), Red Lake (2005), NIU and likely, Virginia Tech (2007).

SSRIs have non-behavioral perks both sides agree on: life-threatening serotonin syndrome when taken with migraine drugs, gastrointestinal bleeding when taken with aspirin, Aleve or Advil and the bone condition, osteoporosis.

Paxil can reduce or abolish the effect of tamoxifen in breast cancer patients and increase deaths says British Medical Journal. It’s linked to a two-fold increased risk of cardiac birth defects in infants according to its own manufacturer, GSK.

And sex? SSRIs are so linked to dysfunction even the pharma-identified web site WebMD admits many will experience impotence, delayed ejaculation or no orgasm. But there is a solution (besides going off SSRIs) says WebMD: Add another antidepressant that’s not an SSRI, like Wellbutrin!

Effexor, Cymbalta, Pristiq, SNRIs

Selective norepinephrine reuptake inhibitors (SNRIs) are like their SSRIs chemical cousins except their norepinephrine effects can modulate pain, which has ushered in your-depression-is-really-pain, your-pain-is-really-depression and other crossover marketing. But the problem with giving a psychoactive drug for pain is that you’re giving a psychoactive drug for pain. “After three months of taking Savella [another SNRI], I started self-destructing and cutting myself,” writes a 40 year old woman on askapatient.com. “I don’t know why or anything, but it does similar to Prozac where it makes you think and do weird things.”

And Cymbalta, approved this fall for chronic back pain and osteoarthritis?

Cymbalta was the drug healthy 19-year-old volunteer Traci Johnson was testing when she hung herself in an Eli Lilly dorm in 2005. It was the drug Carol Anne Gotbaum killed herself on at Phoenix’s Sky Harbor airport in 2007.

SNRI’s are also harder to quit than SSRIs, especially Effexor. 25-year-old Chicagoan David F. told AlterNet he stood at the top of an 8-story parking lot contemplating jumping every day for weeks after quitting. It’s also the drug Andrea Yates was on when she drowned her five children in 2001.

But not all SNRI side effects are behavioral. The FDA would not approve Pristiq, a newer version of Effexor, when Wyeth/Pfizer tried to market it for vasomotor symptoms, because it caused heart attacks, coronary artery obstruction and hypertension in clinical trials. That’s similar to another SNRI, the diet pill Meridia, which was just withdrawn from the market for causing heart problems. Pristiq is still available.

Read the rest of the article here: http://www.alternet.org/story/149078/nation_of_pill_poppers_19_dangerous_drugs_shamelessly_pushed_by_big_pharma?page=entire

« Return to news items


Share

Nursing homes are seeking to end the psychiatric drug stupor

Sunday, December 5th, 2010

Note from CCHR: The wholesale psychiatric drugging of the elderly in both private and public nursing homes has reached epidemic levels, with the use of antipsychotics, antianxiety drugs (tranquilizers) and antidepressants  skyrocketing and patients being harmed and killed as a direct result.  These drugs are highly dangerous when prescribed to anyone, but when prescribed to the elderly the risks for diabetes, stroke and sudden death are greatly increased.    As stated in the article below, ” Instead of looking for causes of disruptive behavior among dementia patients, doctors typically prescribe drugs to mask the symptoms… because it’s the easy thing to do. … That’s true in hospitals, in clinics and in nursing homes.” It is for this reason we feel the more humane non-drug approach being undertaken by this particular chain of nursing homes in treating elderly patients  suffering from dementia should not only be commended, but employed by all nursing homes caring for the elderly.

The Star Tribune – Dec 4, 2010

by Warren Wolfe

Instead of treating behavioral problems with antipsychotic drugs, the Ecumen chain of 15 homes is using strategies including aromatherapy, massage, music, games, exercise and good talk. The state is helping out.

The aged woman had stopped biting aides and hitting other residents. That was the good news.

But in the North Shore nursing home’s efforts to achieve peace, she and many other residents were drugged into a stupor — sleepy, lethargic, with little interest in food, activities and other people.

“You see that in just about any nursing home,” said Eva Lanigan, a nurse and resident care coordinator at Sunrise Home in Two Harbors, Minn. “But what kind of quality of life is that?”

Working with a psychiatrist and a pharmacist, Lanigan started a project last year to find other ways to ease the yelling, moaning, crying, spitting, biting and other disruptive behavior that sometimes accompany dementia.

They wanted to replace drugs with aromatherapy, massage, games, exercise, personal attention, better pain control and other techniques. The entire staff was trained and encouraged to interact with residents with dementia.

Within six months, they eliminated antipsychotic drugs and cut the use of antidepressants by half. The result, Lanigan said: “The chaos level is down, but the noise is up — the noise of people laughing, talking, much more engaged with life. It’s amazing.”

Now the home’s operator, Shoreview-based Ecumen, has started a project called Awakenings throughout its 15 long-term care nursing homes. It’s based on Lanigan’s work and funded with a two-year, $3.7 million state grant.

“We saw what Eva was doing — something everybody in the industry talks about — and we were impressed,” said Mick Finn, an Ecumen vice president. “We said, ‘Hey, this is real. Can we all do this?’ ”

The dangers of drugs

Powerful antipsychotic drugs have been used for years to reduce agitation, hallucinations and other debilitating symptoms among people with mental illnesses.

They also are widely used “off label” to quell disruptive behavior among people with Alzheimer’s disease and other forms of dementia.

Medicare spends more than $5 billion a year on those drugs for its beneficiaries, including about 30 percent of nursing home residents. Several studies have concluded that more than half are prescribed inappropriately. The drugs are especially hazardous to older people, raising the risk of strokes, pneumonia, confusion, falls, diabetes and hospitalization.

“There’s a bunch of problems, not least of which is those drugs can kill you,” said Dr. Mark Kunik at Baylor College of Medicine in Houston who spoke last month at the Gerontological Society of America’s annual meeting in New Orleans.

Instead of looking for causes of disruptive behavior among dementia patients, doctors typically prescribe drugs to mask the symptoms, he said, because “It’s the easy thing to do. … That’s true in hospitals, in clinics and in nursing homes.”

Federal regulators are cracking down on homes that don’t routinely reassess residents on psychotropic drugs. But use remains widespread.

“Whether you have Alzheimer’s or not, there’s a reason people get frustrated or upset — pain, urinary tract infections, hunger, fear of strangers or loud noises or strange settings, maybe drug interactions,” Kunik said. “If you figure that out, you likely can find a safer, nonpharmacologic treatment.”

Treating loss with love

About 150 miles south of Two Harbors, Bernice Brockelman, 91, was snacking on cookies last Wednesday beside the Christmas tree at Ecumen Parmly LifePointes, a nursing home in Center City — all the while alternating quickly from calm to worry to calm.

“Can I stay here tonight? I don’t know where to go. Can I stay with you?” she asked Christy Johnson, the home’s therapeutic recreation director. Though Johnson reassured her, she asked the question again — and again and again.

In an effort to calm her while preparing to wean her from pills, the Parmly staff invited Brockelman into a game of Bingo and to recite the Polish phrases she learned from her immigrant parents. Then she spotted a male visitor.

“Hey, is he married?” she asked with a sparkle in her eye.

“When she’s feeling good, Mom’s an outrageous flirt and she can be really funny,” said her daughter, Judy Balthazor of Center City. “But often there is the repetitive questions, the worry, sometimes just being washed out. I can’t wait for them to get her off her drugs.”

Until the Awakenings project, few at the home knew Brockelman’s whole story — the loss of both parents when she was in high school, of her husband at age 46, then two sons, a close friend and a nephew. Found to have psychosis and dementia, she “just shut down because she had so many losses,” Balthazor said.

Now, the Parmly staff is gaining deeper knowledge of 15 residents who are on psychotropic drugs and who frequently are agitated or upset. They are about to start weaning the residents from the drugs, but they’ve already started a range of activities tailored to each.

Some say nursing homes cannot afford to replace drugs with personal attention because it requires too much staff time.

“Our guess is that it will take the equivalent of two extra people at each home, spread across all job categories,” said Finn, Ecuman’s vice president. “Can we afford it? We think we have to, because it’s the right thing.”

Brockelman, who lived nearly all of her life in northeast Minneapolis, loved to bake, so now she helps make bread and cookies. She danced and was physically active, so she walks with an aide and taps her toes to polka music. A devout Catholic, she attends several weekly church services. She plays Bingo with aide Jenna Miller and sometimes other residents.

“When [you] understand who Beatrice has been in the past, you know her a lot better in the present,” Miller said. “With the Awakenings project, I have permission to spend the time I need with Bernice so she feels safe and loved.”

http://www.startribune.com/lifestyle/health/111326224.html?page=1&c=y

« Return to news items


Share